Migraine: epidemiology and systems of care
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Migraine is a neurovascular disorder that affects over 1 billion people worldwide. Its widespread prevalence, and associated disability, have a range of negative and substantial effects not only on those immediately affected but also on their families, colleagues, employers, and society. To reduce this global burden, concerted efforts are needed to implement and improve migraine care that is supported by informed health-care policies. In this Series paper, we summarise the data on migraine epidemiology, including estimates of its very considerable burden on the global economy. First, we present the challenges that continue to obstruct provision of adequate care worldwide. Second, we outline the advantages of integrated and coordinated systems of care, in which primary and specialist care complement and support each other; the use of comprehensive referral and linkage protocols should enable continuity of care between these systems levels. Finally, we describe challenges in low and middle-income countries, including countries with poor public health education, inadequate access to medication, and insufficient formal education and training of health-care professionals resulting in misdiagnosis, mismanagement, and wastage of resources.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | The Lancet |
| Vol/bind | 397 |
| Udgave nummer | 10283 |
| Sider (fra-til) | 1485-1495 |
| Antal sider | 11 |
| ISSN | 0140-6736 |
| DOI | |
| Status | Udgivet - 17 apr. 2021 |
Bibliografisk note
Funding Information:
MA is a consultant, speaker or scientific advisor for AbbVie, Allergan, Amgen, Alder, Biohaven, Eli Lilly, Lundbeck, Novartis, and Teva, and primary investigator for Alder, Amgen, Allergan, Eli Lilly, Lundbeck, Novartis and Teva trials. MA has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associate editor of Cephalalgia, and associate editor of the Journal of Headache and Pain. MA is president of the International Headache Society. DCB has served as a consultant to and received research funding from Amgen–Novartis, Allergan, Avanir, Biohaven, Eli Lilly, Promius–Dr Reddy's, and Teva. DCB is on the editorial board of Current Pain and Headache Reports. PP-R has received honoraria for participation in clinical trials and contribution to advisory boards or medical education from Allergan, Almirall, Amgen, Biohaven, Chiesi, Electrocore, Eli Lilly, Medscape, Novartis, and Teva. PP-R's headache research is supported by La Caixa Foundation, AGAUR, Instituto Investigacion Carlos III, Migraine Research Foundation, PERIS, EraNet Neuron, FEDER RIS3CAT, and Novartis. AÖ is on consultant or advisory boards for Allergan, Eli Lilly, Novartis, Teva–Amgen, and Abdi İbrahim İlaç. SS reports consultant, advisory board, or speaker fees for Abbott, Allergan, Eli Lilly, Medscape, Novartis, and Teva. SA reports personal fees from Allergan, Percept, Novartis, Teva, Satsuma, Amgen, Eli Lilly, Supernus, Theranica, Biohaven, and Promius, outside the submitted work. TJS is co-editor of the Journal of Headache and Pain, a director and trustee of Lifting The Burden, and reports personal fees from Eli Lilly, outside the submitted work. RBL serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache, has received research support from the National Institutes of Health, and receives support from the Migraine Research Foundation and the National Headache Foundation. RBL has reviewed for the National Institute on Aging and the National Institute of Neurological Disorders and Stroke, serves as consultant, advisory board member, or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr Reddy's, Electrocore, Eli Lilly, eNeuraTherapeutics, GlaxoSmithKline, Merck, Novartis, Teva, and Vedanta. RBL has received royalties from Wolff's Headache and Informa; and holds stock options in eNeura Therapeutics and Biohaven. All other authors declare no competing interests.
Publisher Copyright:
© 2021 Elsevier Ltd
ID: 285949011